argenx to Report Full Year 2025 Financial Results and Fourth Quarter Business Update on February 26, 2026
argenx (NASDAQ:ARGX) will report full year 2025 financial results and deliver a fourth quarter business update on Thursday, February 26, 2026 at 2:30 PM CET (8:30 AM ET).
Rhea-AI Summary
argenx (NASDAQ:ARGX) will report full year 2025 financial results and deliver a fourth quarter business update on Thursday, February 26, 2026 at 2:30 PM CET (8:30 AM ET).
The company said a live audio webcast and conference call will be available via the Investors section at argenx.com/investors, with a replay available for about one year. Dial-in access code: 3810049.
Details
News Market Reaction – ARGX
On Feb 19, the day this news came out, ARGX closed 0.23% above the previous close.
Data tracked by StockTitan Argus for the Feb 19 session.
Key Figures
- Earnings call date
- February 26, 2026
- Full year 2025 results and Q4 2025 business update
- Call time CET
- 2:30 PM CET
- Scheduled conference call start time
- Call time ET
- 8:30 AM ET
- Corresponding U.S. Eastern Time for call
- Replay duration
- approximately one year
- Webcast replay availability on argenx website
- Access code
- 3810049
- Code required to join the conference call
- Dial-in US
- 1 888 415 4250
- United States participant dial-in number
- Dial-in Europe
- Multiple numbers
- Belgium, France, Netherlands, UK, Switzerland dial-ins listed
- Dial-in Japan
- 81 3 4578 9081
- Japan participant dial-in number
Historical Context
-
FDA acceptance of VYVGART sBLA with Priority Review and set PDUFA date.
-
Preliminary 2025 net sales update and articulated 2026 strategic priorities.
-
Announcement of presentation at J.P. Morgan Healthcare Conference with webcast.
-
CEO transition to Karen Massey and move of prior CEO to chair role.
-
Discontinuation of UplighTED Phase 3 TED studies for futility after interim review.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
February 19, 2026
Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that it will host a conference call and audio webcast on Thursday, February 26, 2026 at 2:30 PM CET (8:30 AM ET) to discuss its full year 2025 financial results and provide a fourth quarter business update.
A webcast of the live call may be accessed on the Investors section of the argenx website at argenx.com/investors. A replay of the webcast will be available on the argenx website for approximately one year following the presentation.
Dial-in numbers:
Belgium 32 800 50 201
France 33 800 943355
Netherlands 31 20 795 1090
United Kingdom 44 800 358 0970
United States 1 888 415 4250
Japan 81 3 4578 9081
Switzerland 41 43 210 11 32
Use the access code 3810049 to join the call. Please dial in 15 minutes prior to the live call.
About argenx
argenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx developed and is commercializing the first approved neonatal Fc receptor (FcRn) blocker and is evaluating its broad potential in multiple serious autoimmune diseases while advancing several earlier stage experimental medicines within its therapeutic franchises. For more information, visit www.argenx.com and follow us on LinkedIn, Instagram, Facebook, and YouTube.
Media:
Ben Petok
bpetok@argenx.com
Investors:
Alexandra Roy
aroy@argenx.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.